ArticleScientific reports2026
Sarcopenia, myosteatosis and systemic immunoinflammatory index in the prediction of survival in patients undergoing immunotherapy for esophageal cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Survival prediction in patients with esophageal cancer is receiving a lot of attention from sarcopenia, myosteatosis, and systemic immune-inflammatory index (SII). The aim of this study was to investigate the survival prediction value of these parameters in esophageal cancer patients treated with immune checkpoint inhibitors (ICIs). Retrospective analysis of 178 patients with esophageal cancer who received immunotherapy and CT imaging. X-tile plots were utilized to determine optimal survival thresholds for skeletal muscle density (SMD), skeletal muscle index (SMI), and SII. The relationship between these parameters and patients’ overall survival (OS) and progression-free survival (PFS) was explored by Cox regression modeling and survival curve analysis. For OS, the Fine-Gray test was used to analyze competing risks. In addition, correlation and interaction analyses were performed on these indicators. Sarcopenia (mOS 10.3 months vs. 23.6 months; P < 0.001), and myosteatosis (mOS 13.0 months vs. 23.4 months; P = 0.008), high SII (14.4 months vs. 40.7 months; P = 0.002) were associated with poor OS. Multifactorial regression showed that sarcopenia (HR: 2.15; 95%CI: 1.19 ~ 3.88; P = 0.012), myosteatosis (HR: 2.34; 95%CI: 1.31 ~ 4.18; P = 0.004), and high SII (HR: 1.91; 95%CI: 1.15 ~ 3.18; P = 0.013) were the independent risk factors for OS in patients with esophageal cancer, but not for PFS. No significant association was found between sarcopenia, myosteatosis, or a high SII and non-cancer mortality in the competing risk model. In addition, there was a low positive correlation (r = 0.219, P = 0.004) and interaction (p = 0.008) between sarcopenia and myosteatosis. The SMI-SMD-SII score was established, and OS was significantly shorter in patients with score ≥ 2 than in patients with score = 0 and 1 (p < 0.001). This study found that sarcopenia, myosteatosis, and SII correlate significantly with survival in patients with advanced esophageal cancer receiving immunotherapy. However, the OS-PFS discrepancy may be confounded by subsequent therapies and does not directly reflect initial efficacy. Prospective studies are needed to validate these findings and inform personalized treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.